Lataa...
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
The epidermal growth factor receptor (EGFR, HER1) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). After initial promising results with EGFR‐targeted therapies such as cetuximab, therapeutic resistance has become a major clinical problem, and new treatment options are theref...
Tallennettuna:
| Julkaisussa: | Mol Oncol |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5983215/ https://ncbi.nlm.nih.gov/pubmed/29603584 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12197 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|